High-dose therapy and autologous hematopoietic stemcell transplantation has been utilized to treat patients with Hodgkin's disease since the mid-1980s [1] . Hodgkin's disease has been one of the most frequent indications for autologous hematopoietic stem-cell transplantation with approximately 1300 patients being treated each year and reported to the North American Autologous Bone Marrow Transplant Registry. Long-term follow-up of patients undergoing autotransplantation for Hodgkin's disease has demonstrated that this treatment has real curative potential [2, 3] , with patients who have been followed for as long as 10 years remaining in remission. In this issue of Annals of Oncology, investigators form Yale University add to this body of knowledge.
Controversy about the utilization of high-dose therapy and autologous hematopoietic stem-cell transplantation to treat patients with Hodgkin's disease has focused on the optimal timing of the therapy and the relative merits of this approach versus further standard therapy. One randomized trial has been carried out in patients with relapsed Hodgkin's disease comparing autologous hematopoietic stem-cell transplantation utilizing high doses of carmustine, etoposide, cytarabine, and melphalan (i.e., BEAM) to lower doses of the same agents [4] . This trial was stopped after the entry of only 40 patients because of a significantly superior event-free (53% vs. 10%) and progression-free survival in the patients undergoing high-dose therapy. However, the overall survival between the two groups was not significantly different. A case control study comparing high-dose therapy and autologous transplantation in 60 patients with primary refractory or relapsed Hodgkin's disease was carried out comparing results with transplantation to a matched group of 103 patients who received conventional salvage therapy [5] . Both disease-free survival (53% vs. 27%) and freedom from progression (63% vs. 32%) significantly favored patients undergoing high-dose therapy and autotransplantation. However, once again, the overall survival (54% vs. 47%) was not significantly different.
High-dose therapy and autologous hematopoietic stem-cell transplantation has been utilized as part of the initial therapy for patients with high-risk Hodgkin's disease [6] but the indications for utilizing autotransplantation as part of the primary therapy remain uncertain because of the curative potential of standard treatment, even in poor risk patients. For patients who fail to achieve an initial complete remission it is now clear that high-dose therapy and autologous transplantation is the treatment of choice [7] [8] [9] . Approximately 30%-40% of these patients can achieve durable remissions with highdose therapy and autologous transplantation. A case control study has confirmed the superiority of this treatment approach [8] .
There has been some controversy regarding the timing of high-dose therapy and autologous transplantation for patients who relapse from complete remission. Because patients who have remissions lasting longer than one year can some times be cured with further standard therapy [10, 11] , the appropriateness of transplantation for such patients has been questioned. However, on prolonged follow-up, even patients with long initial remission have a poor ultimate survival with further standard dose salvage therapy [12] . Two series of patients with Hodgkin's disease who underwent transplant at first relapse from complete remission found a failure-free survival of 40%-60% [13, 14] . Patients with both brief and prolonged initial remission can achieve durable remissions with this treatment approach. Although there are no randomized trials, transplantation appears superior for patients with a brief initial remission and, probably, superior for patients with longer initial remissions.
The best way to carry out high-dose therapy and autotransplantation for patients with Hodgkin's disease remains uncertain. Most patients undergo transplantation using either BEAM or cyclophosphamide, carmustine, and etoposide (CBV). Patients receive autologous hematopoietic stem cells obtained from the bone marrow or blood to alleviate otherwise serious and possibly fetal hematopoietic toxicity. A previous publication had raised concerns over the use of peripheral blood derived hematopoietic stem cells [15] . The article by Argiris et al. in this issue of Annals of Oncology [16] suggests that autologous peripheral blood-cell transplantation is as effective as autologous bone marrow transplantation. However, in the absence of a randomized trial comparing the two approaches for patients with Hodgkin's disease, this question cannot be answered definitively. It is also the policy at our institution to use autologous peripheral blood derived hematopoietic stem cells for autotransplantation when treating patients with Hodgkin's disease.
High-dose therapy and autotransplantation has become an accepted therapy for patients with Hodgkin's disease who fail to be cured with standard chemotherapy regimens. Its ultimate place as a component of the initial therapy for patients who present with very high risk disease remains uncertain and will await the results of ongoing trials. It is unlikely that more randomized trials in patients with primary refractory or relapsed disease will be carried out because of the weight of evidence of the efficacy of transplantation in these clinical settings. Further improvements in supportive care, denning the best stem-cell source, and better high-dose regimens, are likely to improve the already good results.
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